Nuedexta (Dextromethorphan,Quinidine)

Quick links

Choose a section

Quick links to important sections

Advertisements

Nuedexta (Dextromethorphan,Quinidine)

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Nuedexta (Dextromethorphan,Quinidine)

Quick Facts

Property Description
Active ingredient Dextromethorphan Hydrobromide, Quinidine Sulfate
Form Hard Gelatin Capsule (Oral)
Pharmacological class Miscellaneous Central Nervous System (CNS) Agent
Common use Treatment of Pseudobulbar Affect (PBA)
Origin Fixed-dose combination of synthetic and derived compounds

What is Nuedexta (Dextromethorphan/Quinidine) and its Core Classification?

Nuedexta is a distinctive prescription-only fixed-dose combination product classified as a Miscellaneous Central Nervous System (CNS) Agent. This medication is clinically recognized for its targeted action within the brain and spinal cord, where it modulates the neurological pathways responsible for emotional regulation. Its unique identity lies in the combination of two historically distinct compounds—Dextromethorphan and Quinidine—engineered into a single therapeutic entity to achieve an effect neither compound can reliably achieve alone.


Composition: The Dextromethorphan/Quinidine Dual-Ingredient Principle

The medicine is supplied as an oral hard gelatin capsule containing the two active ingredients: Dextromethorphan Hydrobromide and Quinidine Sulfate. Dextromethorphan acts as the primary neurotherapeutic agent, while Quinidine, an established antiarrhythmic agent, is included solely as a CYP450 2D6 inhibitor. This composition represents a clear pharmacokinetic strategy, ensuring the therapeutic component remains active in the system for the required duration. This formulation is distinctive because it repurposed Quinidine for its metabolic function rather than its cardiac effects.


General Purpose of the Fixed Combination

The general purpose of the Dextromethorphan/Quinidine combination is the treatment of Pseudobulbar Affect (PBA), a neurological condition characterized by sudden, frequent, and uncontrollable episodes of laughing or crying that are often disconnected from the patient’s underlying mood. This fixed-dose strategy is necessary because Quinidine prevents the rapid metabolism of Dextromethorphan, thereby allowing adequate therapeutic concentrations to be sustained within the CNS. The combination aims to stabilize the abnormal emotional control signals, providing patients with better management of these involuntary PBA symptoms.

Regulatory References

  1. MedlinePlus Drug Information
Advertisements

What side effects are possible with Nuedexta (Dextromethorphan,Quinidine)?

Possible Side Effects and Safety Information

The safety profile of Nuedexta is defined by common adverse reactions and serious risks primarily related to its quinidine component. All side effects listed below are based on official government regulatory documents.

Common and Expected Adverse Reactions

Adverse reactions are classified by frequency based on clinical study data:

  • Very Common (Affecting 10% or more): Diarrhea.
  • Common (Affecting 1% to 10%): Dizziness, Vomiting, Cough, Asthenia (weakness), Peripheral Edema, Urinary Tract Infection, Flatulence.

These effects primarily involve the Gastrointestinal and Nervous Systems and are organized by System Organ Class (SOC) in official labeling.

Serious Adverse Reactions and Safety Restrictions

The most serious documented risk is QT c interval prolongation, which can lead to a potentially fatal irregular heart rhythm called Torsades de Pointes (TdP). This risk is dose-dependent and necessitates mandatory cardiac monitoring.

Serious Adverse Reactions documented in regulatory sources include:

  • QT c Interval Prolongation and TdP.
  • Hepatotoxicity (liver injury).
  • Thrombocytopenia (low platelet count).
  • Severe hypersensitivity reactions.

Contraindications (Situations where use is forbidden):

  • Congenital long QT syndrome, history of TdP, or complete AV block without a pacemaker.
  • Concomitant use with drugs that both prolong the QT c interval and are metabolized by the CYP2 D6 enzyme.
  • Severe hepatic impairment or a history of quinidine-induced hepatitis or thrombocytopenia.

Population-Specific Considerations

Safety notes emphasize careful consideration for use in the elderly and in patients with renal or hepatic impairment, often requiring specific monitoring or dose adjustments as defined by the regulator.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

An overdose of Dextromethorphan/Quinidine is associated with potential manifestations affecting multiple body systems, as documented in regulatory labeling. Documented clinical presentations include central nervous system (CNS) effects such as dizziness, headache, confusion, unusual excitement, abnormal thinking, changes in muscle reflexes, and loss of coordination. Gastrointestinal symptoms like nausea, vomiting, and diarrhea are also listed, along with sensory disturbances such as ringing in the ears (tinnitus) and blurred or double vision.

Severe Outcomes and Emergency Actions

The official regulatory profile highlights the risk of severe, life-threatening outcomes. These include dose-dependent QTc prolongation, which can lead to Torsades de pointes-type ventricular tachycardia, and the potential for Serotonin Syndrome. Neurological emergencies such as seizures and loss of consciousness are also documented severe manifestations. Increased drug exposure and toxicity are noted as likely in patients with severe renal or hepatic impairment.

The regulator-mandated instruction is to seek immediate medical attention by calling emergency services if the affected individual has collapsed, experienced a seizure, is having trouble breathing, or cannot be awakened (loss of consciousness). Management is primarily symptomatic and supportive, requiring Electrocardiographic (ECG) evaluation to monitor the QTc interval and correction of electrolyte imbalances.

Advertisements

Therapeutic Uses of Nuedexta (Dextromethorphan,Quinidine)

What Nuedexta (Dextromethorphan/Quinidine) treats: main uses and benefits


Nuedexta is commonly used for managing Pseudobulbar Affect (PBA), a distinct neurological condition. This condition is generally characterized by involuntary, sudden, and frequent episodes of crying and/or laughing that are often out of proportion to the patient's internal emotional state. The medication may assist with managing the severity and frequency of these disruptive outbursts, contributing to maintaining functional stability.

This supportive treatment is commonly used across conditions presenting with episodic or fluctuating manifestations of PBA, including those associated with Multiple Sclerosis (MS), Amyotrophic Lateral Sclerosis (ALS), and a history of stroke. By helping to moderate these pronounced, involuntary emotional manifestations, the treatment provides supportive relief that assists patients in coping more steadily with difficult episodes.

This approach is relevant when symptoms may interfere with daily comfort and social interaction. The drug contributes to easing the overall symptom load, and may assist with improved day-to-day comfort and supports general well-being during symptomatic phases.

Quick Facts

  • Relief Domain: Relevant for managing symptoms related to Involuntary Emotional Outbursts.

Regulatory References

  1. NIH DailyMed drug label
Advertisements

Eligibility and Restrictions for Use

Nuedexta is officially indicated only for adults (18 years and older) who have a diagnosis of Pseudobulbar Affect (PBA). The medicine is strictly contraindicated and must not be used in several populations, primarily due to the cardiovascular risks associated with the quinidine component.

Absolute contraindications include patients with a prolonged QT interval, congenital long QT syndrome, heart failure, or complete atrioventricular (AV) block without a pacemaker. Use is also strictly prohibited in patients who are currently taking a Monoamine Oxidase Inhibitor (MAOI), or have taken one within the preceding 14 days. Concomitant use with other quinidine-containing medicines or drugs that both prolong the QT interval and are metabolized by CYP2D6 is also forbidden.

Eligibility is not established in pediatric patients (under 18 years) because safety and effectiveness have not been evaluated in this group. For geriatric patients, cautious dose selection is advised. Similarly, use has not been evaluated in patients with severe hepatic or severe renal impairment. During pregnancy and lactation, use is permitted only if the potential benefit justifies the possible risk.

Advertisements

What should I know about interactions with other medicines?


Key Drug Interactions and Restrictions

Nuedexta carries a risk for clinically significant drug interactions due to the quinidine component, which acts as a potent inhibitor of the CYP2D6 enzyme and the P-glycoprotein (P-gp) transporter. This mechanism can lead to increased concentrations of co-administered medicines that are metabolized by CYP2D6 or transported by P-gp.

Contraindicated Combinations

  • Monoamine Oxidase Inhibitors (MAOIs): Concurrent use, or use within 14 days of stopping an MAOI, is strictly prohibited due to the risk of serotonin syndrome, a serious and potentially fatal condition. A 14-day washout period is also required after discontinuing Nuedexta before starting an MAOI.
  • Quinidine and Related Drugs: Use with other medicines containing quinidine, quinine, or mefloquine is contraindicated, as Nuedexta contains quinidine.
  • QT-Prolonging CYP2D6 Substrates: The combination is contraindicated with drugs that both prolong the QT interval and are metabolized by CYP2D6 (e.g., thioridazine, pimozide) due to an increased risk of QTc prolongation and Torsades de Pointes-type ventricular tachycardia.

Required Monitoring and Dose Adjustments

  • Serotonergic Agents: Use with Selective Serotonin Reuptake Inhibitors (SSRIs) or Tricyclic Antidepressants (TCAs) increases the risk of serotonin syndrome and requires caution and monitoring.
  • CYP2D6 Substrates: Medicines primarily metabolized by CYP2D6 may require a dose adjustment (e.g., desipramine) or an alternative treatment.
  • P-gp Substrates: Exposure of P-gp substrates, such as Digoxin, may increase; close monitoring of plasma drug levels and dose reduction is necessary.
Advertisements

Mechanism of Action

How Nuedexta (Dextromethorphan/Quinidine) Works

The drug's mechanism relies on a dual-action receptor engagement driven by Dextromethorphan (DM), which is supported by Quinidine's action on metabolism. The mechanism acts to modulate signaling within the Corticopontocerebellar Circuit, a neurological pathway that controls emotional reflexes.


Targeting sigma1 and NMDA Receptors

Dextromethorphan acts as an agonist at the Sigma-1 (sigma1) receptor and a non-competitive antagonist at the NMDA receptor. This dual approach reduces excessive excitatory signaling and results in a state of neurological stabilization. The physiological effect is the augmentation of inhibitory tone over brainstem nuclei, which alters the pattern of spontaneous electrical activity.


Enzyme Inhibition for Sustained Mechanism

The second component, Quinidine, acts as an inhibitor of the CYP2D6 enzyme. This serves as a pharmacokinetic/pharmacodynamic link. By inhibiting this enzyme, Quinidine prevents the rapid metabolic breakdown of Dextromethorphan, which allows for the sustained presence of the parent drug within the central nervous system required to engage its targets.

Advertisements

Dosage and Administration Information

Official Administration Guidelines: Dosing and Schedule

Nuedexta is administered solely via the oral route as a fixed-dose hard gelatin capsule. The standard dose is a combination of 20 mg Dextromethorphan Hydrobromide and 10 mg Quinidine Sulfate per capsule.

The usage protocol follows a seven-day titration schedule before transitioning to the long-term maintenance dose:

Treatment Phase Dosing Frequency Capsule Count & Strength Constraint
Initial (Days 1–7) Once daily One capsule (20 mg DM/10 mg QN) None
Maintenance (Day 8+) Twice daily One capsule every 12 hours Do not exceed 2 capsules/24 hours

Administration Conditions and Patient-Specific Rules

Capsules can be taken with or without food. If a dose is missed, an extra or double dose must not be taken; the patient should simply resume the schedule by taking the next dose at the usual time. The total daily intake is strictly limited to two capsules.

Treatment is typically considered a long-term therapy, and the need for continued use should be periodically reassessed. For patients with mild or moderate renal or hepatic impairment, a specific dose adjustment is not required. The medication is not indicated for the pediatric population, as safety and efficacy have not been established in this age group.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section provides a summary of the clinical and preclinical research conducted on the substance. It is a neutral description of the studies that were performed.


Mechanism of Action: Preclinical Studies

Preclinical and clinical research has investigated how the drug interacts with the Sigma-1 receptor pathway. Studies explored the relationship between the substance and inflammation markers such as IL-6 and TNF-alpha.

  • Preliminary Findings: In preliminary research, the substance was observed to interact with the Sigma-1 receptor.
  • Cellular Assessment: Animal models were used to assess changes in pro-inflammatory genes following administration of the substance. Data from preclinical investigations suggested a difference in cellular uptake relative to similar compounds.

Clinical Efficacy: Phase 2 and 3 Trials

Research has investigated the use of the drug in participants with Pseudobulbar Affect (PBA), which is the sole approved indication.

PBA Studies

A key Phase 3 study observed a change in the frequency and severity of crying and laughing episodes in participants over the study period, as measured by the CNS-LS (Center for Neurologic Study-Lability Scale). This study evaluated the drug's use in participants with PBA associated with underlying neurologic conditions like multiple sclerosis (MS) or amyotrophic lateral sclerosis (ALS).

  • Symptom Assessment: Clinical trials assessed the frequency of PBA episodes among participants taking the drug. The onset of reported changes in symptoms was a measured endpoint in some research.

Safety and Tolerability Profile

Clinical trials reported on safety and tolerability in participants, including those with conditions such as mild kidney issues. Nausea, headache, and minor gastrointestinal discomfort were among the frequently reported adverse events in the clinical trials.

  • Comparative Safety: Studies compared the side effect profile of the drug with that of placebo. The trials noted differences in the incidence of diarrhea between the drug group and the comparator group.

Key Studies & References

  1. Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis (Study 2, published 2006)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Nuedexta (Dextromethorphan,Quinidine) (FAQ)


Q: What is the difference between Nuedexta and regular cough medicine (dextromethorphan)?

Nuedexta contains Dextromethorphan along with a second ingredient, Quinidine. The Quinidine is included specifically to prevent the rapid metabolic breakdown of Dextromethorphan by the body. This unique combination ensures that the Dextromethorphan remains present in the body for a sustained, longer duration than when taken alone, allowing it to have its targeted effect on the central nervous system.


Q: Are there specific foods or drinks that should be avoided when taking Nuedexta?

Official labeling advises avoiding grapefruit and grapefruit juice. This is because these products can interact with the quinidine component of the medicine. This interaction could potentially lead to higher-than-expected drug levels, which might affect the heart's electrical activity, specifically the QTc interval.


Q: Does Nuedexta cause drowsiness or fatigue?

Regulatory documents indicate that somnolence (drowsiness) and fatigue were among the most commonly reported adverse reactions in clinical trials. Official labeling notes that patients should be cautioned about these effects when considering activities such as driving or operating machinery.


Q: Is Nuedexta safe to take with common antidepressants like SSRIs?

Official warnings state that taking this medication with Selective Serotonin Reuptake Inhibitors (SSRIs) increases the risk of a serious condition called Serotonin Syndrome. Official documents state that this combination involves the need for careful monitoring by a healthcare provider.


Q: Does Nuedexta need to be taken at a specific time of day?

The official maintenance schedule is structured to involve a dose taken approximately 12 hours apart. This schedule aims to maintain consistent therapeutic concentrations of the active ingredients in the body throughout the day.


Q: What kind of monitoring might be required while taking Nuedexta?

Official documents describe that monitoring of heart rhythm (ECG) is often necessary for certain patients prior to and throughout treatment. Monitoring may also be indicated for symptoms such as the worsening of myasthenia gravis.


Q: Does Nuedexta cause digestive issues like diarrhea or constipation?

Yes, digestive issues are frequently reported. Diarrhea is listed as a very common adverse reaction, and constipation is also listed as a common side effect based on data from clinical trials.


Q: What are the signs of a potential allergic reaction to Nuedexta?

Official documentation notes that signs of a potential serious allergic reaction include symptoms such as lightheadedness, chills, fever, nausea, or vomiting. Severe hypersensitivity reactions are a documented risk associated with the medication.


Q: Are there any differences in the effects of Nuedexta based on age or gender?

Studies comparing how the body processes the medicine have indicated no apparent gender differences in the pharmacokinetics. However, differences are noted based on age, with specific cautions advised for the elderly and no established use for the pediatric population.


Q: Does Nuedexta interact with common over-the-counter cold medicines?

The official label warns that the medication is known to add to the effects of other Central Nervous System (CNS) depressants. Because some cold medicines may contain CNS depressants, official documents describe the need for careful consideration when co-administering any over-the-counter products.


Q: Is Nuedexta a controlled substance?

No, Nuedexta is not classified as a controlled substance under the Drug Enforcement Administration (DEA) schedule. It is a prescription-only medication.


Q: Does Nuedexta have a generic version available?

Yes, the FDA has approved a generic version of the Dextromethorphan/Quinidine fixed-dose combination product.


Q: Can Nuedexta affect my ability to drive?

Official warnings advise patients about the potential for CNS-related effects such as somnolence (drowsiness) and dizziness. The official warnings state that patients should be cautioned against activities such as driving or operating machinery if they experience these symptoms.


Q: What is the risk of serious skin reactions with Nuedexta?

The medication is contraindicated for patients with a known hypersensitivity to dextromethorphan, which may present as a rash or hives. Severe hypersensitivity reactions are documented in regulatory sources.


Q: How long does it take for Nuedexta to be out of the body?

Official pharmacokinetic information indicates that the elimination half-life of Dextromethorphan is extended to approximately 13 hours when taken in combination with Quinidine.


Q: Are there any long-term side effects noted in studies for Nuedexta?

Clinical trials provided safety and tolerability data for treatment periods of up to approximately six months (12 weeks plus an 84-day extension). There is no official data available on effects noted beyond this specific period.


Q: Is Nuedexta approved in countries outside of the United States?

Yes, regulatory documentation indicates that the product has received authorization from the European Medicines Agency, meaning it is approved for use in the European Union, in addition to the United States.


Q: Are there official warnings about taking Nuedexta with alcohol?

Official warnings indicate that caution should be exercised regarding alcohol consumption due to the potential for an additive central nervous system depression, which can cause effects like impaired judgment and thinking.


Q: Can Nuedexta impact vision?

Patients are advised about the potential for central nervous system-related side effects, including the possibility of impaired vision. This is listed as a potential effect in official product information.


Q: Does Nuedexta affect blood pressure?

In cases of Serotonin Syndrome, a serious condition related to interactions with certain other drugs, official warnings note that changes may include the occurrence of hypertension (high blood pressure).


Q: Is it possible to become dependent on Nuedexta?

Official labeling addresses the potential for drug abuse and dependence related to the Dextromethorphan component. This is noted as a concern by regulatory bodies that review the product.


Q: Can Nuedexta cause problems with sleep?

Somnolence (drowsiness) is listed as a commonly reported side effect in official documents, which may affect an individual's sleep patterns.

Advertisements

How should Nuedexta (Dextromethorphan,Quinidine) be stored and disposed of?

Nuedexta capsules must be stored at Controlled Room Temperature, which is defined as 68 F to 77 F (20 C to 25 C). The medication must be kept in the container in which it was dispensed and the cap must remain tightly closed.

Storage must occur in a dry place, away from both excess heat and moisture.

For safety, the medication must be kept out of the reach of children and pets, ideally stored in a safe, locked location. Any unused or expired Nuedexta must be disposed of properly. Consult a pharmacist for specific instructions regarding the appropriate disposal method for the unused product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nuedexta (Dextromethorphan,Quinidine) found in:

A-Z Index: